Regeneron's antibody drug shows protection against COVID-19

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period following the drug's administration.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting